TCRX

TScan Therapeutics, Inc. (TCRX) - 10-Q Summary

Business Context and Reporting Period

This Quarterly Report on Form 10-Q covers the period ended June 30, 2026. TScan Therapeutics, Inc. is a clinical-stage biotechnology company developing T cell receptor (TCR)-engineered T cell (TCR-T) therapies for cancer. The company is classified as an emerging growth company and a smaller reporting company. Its lead product candidate, TSC-101, targets hematologic malignancies (AML and MDS) in patients undergoing allogeneic hematopoietic cell transplantation (HCT).

Key Financial Metrics

Note: Revenue is derived solely from collaboration and license agreements, primarily with Amgen. The company has no product sales revenue.

Material Changes vs. Prior Period

• Revenue Decline: Revenue decreased to $1.1 million for the three months ended June 30, 2026, from $3.1 million in the same period in 2025. This is attributed to the timing of research activities under the Amgen collaboration agreement.
• Expense Reduction: Total operating expenses decreased by approximately $10.2 million quarter-over-quarter. Research and Development (R&D) expenses dropped $9.2 million, primarily due to a $6.8 million decrease in laboratory supplies and a $2.1 million reduction in personnel expenses following a workforce reduction of approximately 30% in November 2025.
• Debt Structure Change: The company did not achieve a specified financial milestone by June 30, 2026, regarding its Silicon Valley Bank (SVB) loan. Consequently, the interest-only period for the $32.5 million term loan will end on September 30, 2026, requiring monthly principal and interest payments thereafter.
• Cash Burn: Net cash used in operating activities was $51.8 million for the six months ended June 30, 2026, compared to $70.9 million in the prior year period, reflecting the reduced operating expenses.

Guidance, Outlook, and Risks

• Going Concern Warning: Management has identified conditions that raise substantial doubt about the company's ability to continue as a going concern for twelve months following the filing date. Existing cash and cash equivalents ($100.2 million) are expected to fund operations only into the second quarter of 2027.
• Capital Needs: The company will require substantial additional funding to complete development and commercialization. Strategies to obtain funding may include equity offerings, debt financing, or collaborations, all of which carry risks of dilution or restrictive covenants.
• Clinical Progress: The company announced the first patient dosing in the Phase 3 ALLOHA-2 trial for TSC-101 in July 2026. It is also expanding its pipeline with TSC-102 candidates for different HLA types and exploring in vivo engineering for solid tumors.
• Key Risks:
  • Failure to raise additional capital on acceptable terms.
  • Delays or failures in clinical trials and regulatory approvals.
  • Restrictions on operating flexibility due to the SVB loan agreement.
  • Global economic uncertainty and potential impacts of U.S. policy changes (e.g., tariffs, healthcare policy).

Investor Verification Checklist

• Liquidity Runway: Verify the specific timeline for cash exhaustion and the status of any new financing discussions, given the "substantial doubt" going concern disclosure.
• Debt Obligations: Confirm the impact of the SVB loan transitioning from interest-only to principal-and-interest payments starting October 2026 on future cash flow.
• Amgen Collaboration: Review the terms of the Amgen agreement to understand the variability in revenue recognition and the potential for future milestone payments.
• Workforce Impact: Assess the long-term operational impact of the 30% workforce reduction announced in late 2025 on clinical trial execution and R&D velocity.
• Phase 3 Trial Status: Monitor enrollment rates and safety data for the Phase 3 ALLOHA-2 trial, which is critical for the company's primary value proposition.